Comment: TB47 is a preclinical antitubercular drug candidate, designed using scaffold hopping and SAR-based chemical modification strategies [
2]. It is an inhibitor of mycobacterial QcrB, the cytochrome b subunit of the cytochrome bcc complex (also known as complex III) [
1,
5].